Correlation Between Orexo AB and Sprint Bioscience

Can any of the company-specific risk be diversified away by investing in both Orexo AB and Sprint Bioscience at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Orexo AB and Sprint Bioscience into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Orexo AB and Sprint Bioscience AB, you can compare the effects of market volatilities on Orexo AB and Sprint Bioscience and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Orexo AB with a short position of Sprint Bioscience. Check out your portfolio center. Please also check ongoing floating volatility patterns of Orexo AB and Sprint Bioscience.

Diversification Opportunities for Orexo AB and Sprint Bioscience

-0.71

Correlation Coefficient

Orexo AB  Sprint Bioscience

Pay attention - limited upside

The 3 months correlation between Orexo and Sprint is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Orexo AB and Sprint Bioscience AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sprint Bioscience and Orexo AB is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Orexo AB are associated (or correlated) with Sprint Bioscience. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sprint Bioscience has no effect on the direction of Orexo AB i.e., Orexo AB and Sprint Bioscience go up and down completely randomly.

Pair Corralation between Orexo AB and Sprint Bioscience

Assuming the 90 days trading horizon Orexo AB is expected to under-perform the Sprint Bioscience. But the stock apears to be less risky and, when comparing its historical volatility, Orexo AB is 1.34 times less risky than Sprint Bioscience. The stock trades about -0.06 of its potential returns per unit of risk. The Sprint Bioscience AB is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  131.00  in Sprint Bioscience AB on August 31, 2024 and sell it today you would earn a total of  53.00  from holding Sprint Bioscience AB or generate 40.46% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	98.46%
Values	Daily Returns

Orexo AB  vs.  Sprint Bioscience AB

Orexo AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Orexo AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Sprint Bioscience

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Orexo AB and Sprint Bioscience

The main advantage of trading using opposite Orexo AB and Sprint Bioscience positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Orexo AB position performs unexpectedly, Sprint Bioscience can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sprint Bioscience will offset losses from the drop in Sprint Bioscience's long position.

The idea behind Orexo AB and Sprint Bioscience AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.